Welcome to our dedicated page for Novocure news (Ticker: NVCR), a resource for investors and traders seeking the latest updates and insights on Novocure stock.
NovoCure Limited develops and commercializes Tumor Treating Fields therapy for solid tumors through wearable medical devices including Optune Gio, Optune Lua and Optune Pax. News about NVCR centers on product approvals, reimbursement decisions, launch activity and the use of TTFields in glioblastoma, pancreatic cancer, non-small cell lung cancer and pleural mesothelioma.
Company updates also cover clinical programs such as PANOVA, LUNAR and KEYNOTE studies, quarterly financial results, research and clinical-study spending, and commercialization across the United States, Europe, Japan and other markets where the company has approved products.
Novocure (NASDAQ: NVCR) has announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program, collaborating with the American Association for Cancer Research. The initiative allocates over $1.5 million in research grants over three years to support innovative studies on Tumor Treating Fields (TTFields) therapy. This includes three grants of $350,000 for independent researchers and one $300,000 Career Development Award aimed at junior faculty. The application deadline is set for May 30, 2023. Novocure seeks to enhance understanding of TTFields mechanisms to improve cancer treatment options.
Optune is now a reimbursed treatment for newly diagnosed glioblastoma patients in France.
Novocure (NASDAQ: NVCR) announced that Optune is available alongside temozolomide (TMZ) for adult patients with glioblastoma (GBM). This follows its registration as a reimbursable product published in the Official Journal on February 28, 2023, effective March 15, 2023. Optune utilizes Tumor Treating Fields (TTFields) to disrupt cancer cell division and has treated over 27,000 patients worldwide. Clinical data from a phase 3 study showed median overall survival improved to 20.9 months with TTFields-TMZ versus 16.0 months with TMZ alone.
Novocure (NASDAQ: NVCR) has completed enrollment in the pivotal METIS study, which evaluates Tumor Treating Fields (TTFields) therapy post-stereotactic radiosurgery (SRS) for patients with brain metastases from non-small cell lung cancer (NSCLC). The study enrolled 270 adult patients and focuses on various endpoints, including time to first intracranial progression. Novocure anticipates final data in 2024, marking a significant period for the company and treatment of solid tumor cancers. This study is the fourth pivotal trial completed by Novocure in 17 months, with a steady flow of new data expected through 2024.
Novocure (NASDAQ: NVCR) announced the election of Dr. Allyson J. Ocean to its Board of Directors. Dr. Ocean is a prominent medical oncologist with expertise in gastrointestinal oncology, currently serving at Weill Cornell Medicine. Her role is expected to enhance Novocure’s mission to extend survival in aggressive cancers through innovative therapies. She is also co-founder of a non-profit focused on pancreatic cancer treatment access. Novocure is known for its Tumor Treating Fields, a revolutionary therapy approved for conditions such as glioblastoma and malignant pleural mesothelioma, with ongoing studies in various cancers.
Novocure (NASDAQ: NVCR) reported its financial results for Q4 and the full year 2022, achieving net revenues of $538 million for the year and $128 million for the quarter. The pivotal LUNAR study in non-small cell lung cancer successfully met its primary and secondary overall survival endpoints. Novocure completed enrollment for the pivotal PANOVA-3 study in pancreatic cancer and is nearing completion of the METIS study in brain metastases. Despite a 4% revenue decline in Q4, the company reported a 78% gross margin and held $969 million in cash as of December 31, 2022.
Novocure (NASDAQ: NVCR) has completed patient enrollment in the pivotal PANOVA-3 study, assessing the efficacy of Tumor Treating Fields (TTFields) combined with nab-paclitaxel and gemcitabine in treating locally advanced pancreatic cancer. With approximately 43,000 annual diagnoses in the U.S. and a stagnant five-year survival rate of just 10%, this study represents a significant milestone. The trial will follow patients for at least 18 months, focusing on overall survival as the primary endpoint and several secondary endpoints. The results, expected in 2024, could offer hope for improving survival rates in this challenging cancer type.
Novocure (NASDAQ: NVCR) announced key organizational changes effective January 17, 2023, aiming for growth. Pritesh Shah will become Chief Growth Officer, overseeing product strategy and market access. Ely Benaim will leave as Chief Medical Officer, with interim leadership transitioning to Piet Hinoul. Uri Weinberg becomes Chief Innovation Officer, while Moshe Giladi steps into Chief Science Officer. CEO Asaf Danziger noted the recent positive developments in pivotal studies, signaling a transformative period for the company. Novocure focuses on expanding its Tumor Treating Fields therapy for various cancers.
Novocure (NASDAQ: NVCR) reported preliminary net revenues of $538 million for 2022, with Q4 revenues at $128 million. The successful LUNAR study showed a significant improvement in overall survival for non-small cell lung cancer patients. Active patients on therapy reached 3,430 by year-end 2022. Cash reserves stood at $969 million. The company is set to present at the J.P. Morgan Healthcare Conference on January 10, 2023.
Novocure's LUNAR study achieved its primary endpoint, showing significant improvement in overall survival for stage 4 NSCLC patients treated with Tumor Treating Fields (TTFields) alongside standard therapies.
The study revealed that TTFields combined with immune checkpoint inhibitors (ICI) and docetaxel led to better survival rates compared to standard treatments alone. Novocure plans to submit a Premarket Approval application to the FDA and a CE Mark application in the second half of 2023. This marks a pivotal moment in treating late-stage lung cancer, addressing a critical unmet need.
Novocure (NASDAQ: NVCR) will participate in the 41st Annual J. P. Morgan Healthcare Conference on January 10-11, 2023. Executive Chairman William Doyle will speak at 7:30 a.m. PST on January 10, 2023, addressing analysts' questions. Additionally, Doyle and CFO Ashley Cordova will hold one-on-one meetings with investors. A live audio webcast of the presentation will be available on Novocure's Investor Relations page, along with a replay for at least 14 days post-event. Novocure focuses on extending survival in aggressive cancers through its innovative Tumor Treating Fields therapy.